Risk of bias in industry-funded oseltamivir trials: comparison of core reports versus full clinical study reports
Author
Jefferson, TomJones, Mark A., B.Sc., Ph.D.
Doshi, Peter
Del Mar, Chris
Hama, Rokuro, M.D.
Thompson, Matthew J.
Onakpoya, Igho
Heneghan, Carl
Date
2014-09Publisher
BMJ Publishing GroupType
Article
Metadata
Show full item recordCitation
Jefferson, T., Jones, M.A., Doshi, P., et al. (2014). Risk of bias in industry-funded oseltamivir trials: comparison of core reports versus full clinical study reports. BMJ Open, 4(9). DOI: 10.1136/bmjopen-2014-005253Identifier to cite or link to this item
http://hdl.handle.net/10713/6585ae974a485f413a2113503eed53cd6c53
10.1136/bmjopen-2014-005253
Scopus Count
Collections
Related articles
- Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children.
- Authors: Jefferson T, Jones MA, Doshi P, Del Mar CB, Heneghan CJ, Hama R, Thompson MJ
- Issue date: 2012 Jan 18
- Neuraminidase inhibitors for preventing and treating influenza in adults and children.
- Authors: Jefferson T, Jones MA, Doshi P, Del Mar CB, Hama R, Thompson MJ, Spencer EA, Onakpoya I, Mahtani KR, Nunan D, Howick J, Heneghan CJ
- Issue date: 2014 Apr 10
- The future of Cochrane Neonatal.
- Authors: Soll RF, Ovelman C, McGuire W
- Issue date: 2020 Nov
- Research transparency: a moral obligation.
- Issue date: 2014 Jun
- Neuraminidase inhibitors for preventing and treating influenza in children (published trials only).
- Authors: Wang K, Shun-Shin M, Gill P, Perera R, Harnden A
- Issue date: 2012 Apr 18